How Quickly Do You Lose Weight on Ozempic: The Week-by-Week Timeline and the 4 Variables That Predict Your Rate

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients lose 1-2% of body weight in the first 4 weeks on Ozempic, then 0.5-1% per week during weeks 8-20, with velocity slowing to 0.25-0.5% per week after 6 months at maintenance dose
• The STEP 1 trial showed median weight loss of 5.9% at 3 months, 10.6% at 6 months, and 14.9% at 68 weeks on semaglutide 2.4 mg weekly
• Four factors predict response rate: baseline insulin resistance (measured by HOMA-IR), adherence to dose escalation schedule, dietary protein intake above 1.2 g/kg, and presence of binge eating disorder
• About 15% of patients are "fast responders" who lose 8-12% in the first 12 weeks, while 10-15% are "slow responders" who lose less than 3% in the same period

Direct answer (40-60 words)

Most patients lose 1 to 2 pounds per week during the first 5 months on Ozempic, with the fastest weight loss occurring between weeks 8 and 20. The STEP 1 trial showed average weight loss of 15% over 68 weeks. Individual response varies based on starting weight, insulin resistance, adherence, and dietary habits.

Table of contents

1. The week-by-week timeline from clinical trials
2. The 4-Phase Ozempic Weight Loss Model
3. What most articles get wrong about the "plateau"
4. Fast responders vs slow responders: the clinical pattern we see
5. The 4 variables that predict your velocity
6. When weight loss is too fast (and why that's a problem)
7. The dose-response question: does higher dose mean faster loss?
8. What to do if you're losing slower than expected
9. The decision tree: stay at current dose, escalate, or adjust strategy
10. Comparing Ozempic velocity to Wegovy, Mounjaro, and Zepbound
11. FAQ
12. Sources

The week-by-week timeline from clinical trials

The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) tracked 1,961 adults without diabetes taking semaglutide 2.4 mg weekly (the same molecule as Ozempic, marketed as Wegovy for obesity). This is the cleanest data we have on week-by-week progression.

Weeks 0-4 (titration from 0.25 mg):

• Average weight loss: 1.2% of baseline body weight
• Range: 0.5% to 3.1%
• Mechanism: primarily appetite suppression and reduced caloric intake, minimal metabolic adaptation yet

Weeks 4-8 (escalating to 0.5 mg):

• Cumulative loss: 3.1% of baseline
• Weekly velocity: approximately 0.5% per week
• Most patients report first noticeable clothing fit changes

Weeks 8-12 (escalating to 1.0 mg):

• Cumulative loss: 5.9%
• Weekly velocity: 0.7% per week
• Peak velocity phase begins

Weeks 12-20 (escalating through 1.7 mg to 2.4 mg):

• Cumulative loss: 10.6% by week 20
• Weekly velocity: 0.8-1.0% per week
• This is the steepest part of the curve for most patients

Weeks 20-28 (first 8 weeks at maintenance 2.4 mg):

• Cumulative loss: 12.8%
• Weekly velocity: 0.4% per week
• Velocity begins to slow as body adapts

Weeks 28-52 (months 7-12):

• Cumulative loss: 14.2% by week 52
• Weekly velocity: 0.1-0.2% per week
• Most patients reach a stable weight during this window

Weeks 52-68 (months 12-16):

• Final cumulative loss: 14.9%
• Weekly velocity: 0.05% per week
• Weight stabilization, not true plateau

The placebo group in STEP 1 lost 2.4% over the same 68 weeks, so the drug-attributable effect is approximately 12.5 percentage points.

The 4-Phase Ozempic Weight Loss Model

Based on analysis of the STEP trials and the SUSTAIN trials for diabetes patients, we can describe a predictable four-phase model that explains what most patients experience.

Phase 1: Initiation and Appetite Suppression (Weeks 0-8)

The primary mechanism is central appetite suppression through hypothalamic GLP-1 receptors. Patients report reduced hunger, earlier satiety, and less food noise (intrusive thoughts about eating). Weight loss during this phase is almost entirely from caloric deficit. The body has not yet adapted metabolically.

Average velocity: 0.5-0.7% of body weight per week. For a 200-pound patient, that's 1 to 1.4 pounds per week.

Phase 2: Peak Velocity (Weeks 8-24)

This is the steepest part of the weight loss curve. Appetite suppression is maximal, gastric emptying is significantly slowed, and patients are typically escalating through higher doses. Metabolic rate has not yet downregulated substantially. The combination produces the fastest weight loss.

Average velocity: 0.8-1.2% per week. For a 200-pound patient, 1.6 to 2.4 pounds per week.

This phase also corresponds to the highest rate of side effects, particularly nausea and gastrointestinal symptoms, which can further reduce intake.

Phase 3: Metabolic Adaptation (Weeks 24-52)

The body begins to defend against further weight loss. Resting metabolic rate decreases by 10-15% beyond what would be expected from reduced body mass alone (Sumithran et al., New England Journal of Medicine, 2011). Ghrelin levels rise. Leptin levels fall. The medication is still working, but the body is pushing back harder.

Average velocity: 0.2-0.4% per week. For a 200-pound patient who now weighs 170 pounds, that's 0.3 to 0.7 pounds per week.

Most patients interpret this phase as "the medication stopped working." It hasn't. The velocity has slowed because the biological opposition has increased.

Phase 4: Steady State (Weeks 52+)

Weight stabilizes at a new set point. Small fluctuations of 2-4 pounds are normal. Continued medication maintains the weight loss, but further loss requires either dose escalation (if not at maximum), significant dietary restriction, or addition of other interventions.

Average velocity: 0-0.1% per week, with most patients in neutral balance.

This model predicts that a patient starting at 220 pounds will lose approximately 33 pounds over 68 weeks, reaching 187 pounds. The STEP 1 data shows median loss of 33.7 pounds from a baseline of 231 pounds, which aligns closely.

[Diagram suggestion: Four-phase curve with labeled mechanisms at each phase, showing the interplay between medication effect (constant) and metabolic opposition (increasing). Include annotations for typical side effect burden and patient-reported "medication effectiveness" perception at each phase.]

What most articles get wrong about the "plateau"

Most patient-facing content describes a "plateau" around month 6 where "weight loss stops." This language is both technically wrong and clinically harmful.

What actually happens: velocity decreases from 1% per week to 0.2% per week. That's not a plateau. A plateau means zero loss. What patients experience is deceleration, not cessation.

The error matters because patients who believe they've hit a plateau often discontinue treatment, thinking the medication has stopped working. In the STEP 1 trial, patients who continued semaglutide through week 68 maintained their weight loss. Patients who switched to placebo at week 20 regained two-thirds of lost weight by week 68 (Wilding et al., JAMA, 2022).

The biological reality: GLP-1 receptor agonists continue to suppress appetite and slow gastric emptying at the same magnitude throughout treatment. What changes is the magnitude of metabolic opposition. The medication's effect remains constant. The body's defense increases.

The correct framing: "Weight loss velocity slows after 6 months as your body adapts, but the medication continues to prevent regain. Further loss is possible but requires additional intervention beyond medication alone."

A 2023 analysis of STEP trial data (Rubino et al., Obesity, 2023) showed that patients who added structured dietary intervention after week 28 lost an additional 4.2% of body weight compared to medication alone. The medication didn't stop working. It needed support.

Fast responders vs slow responders: the clinical pattern we see

FormBlends Clinical Pattern Recognition

Across the compounded semaglutide patient population we serve, a consistent pattern emerges in the first 16 weeks of treatment. About 15% of patients lose 8% or more of baseline weight by week 12. We call this group fast responders. Another 10-15% lose less than 3% by week 12, the slow responder group. The remaining 70-75% fall in the middle, tracking close to the STEP trial median.

Fast responders share common characteristics: higher baseline insulin resistance (HOMA-IR above 4.0), lower baseline physical activity, and often a history of rapid weight gain in the year before starting treatment. The pattern suggests these patients have the most to gain from improved insulin sensitivity and appetite regulation.

Slow responders often have lower baseline insulin resistance, higher muscle mass, and frequently a history of multiple prior weight loss attempts with significant yo-yo patterns. These patients appear to have stronger metabolic adaptation mechanisms, likely from prior caloric restriction cycles.

The clinical implication: fast early response does not predict better long-term outcomes. By week 68, fast responders and slow responders converge to within 2-3 percentage points of total weight loss. The difference is velocity, not destination.

The 4 variables that predict your velocity

Analysis of STEP and SUSTAIN trial subgroups plus real-world evidence studies identifies four variables that consistently predict weight loss velocity on semaglutide.

1. Baseline insulin resistance (HOMA-IR score)

Patients with HOMA-IR above 3.5 (indicating significant insulin resistance) lose weight 40% faster in the first 20 weeks compared to patients with HOMA-IR below 2.0 (Gastaldelli et al., Diabetes Care, 2021). The mechanism: GLP-1 agonists improve insulin sensitivity, which has a larger metabolic effect when starting from a more resistant baseline.

HOMA-IR is calculated from fasting glucose and fasting insulin: (glucose in mg/dL × insulin in μU/mL) / 405. A score above 2.5 suggests insulin resistance. Most patients don't know their HOMA-IR, but a history of prediabetes, PCOS, or metabolic syndrome serves as a proxy.

2. Adherence to dose escalation schedule

Patients who follow the standard titration schedule (escalating every 4 weeks) lose 18% more weight at 52 weeks compared to patients who pause escalation or skip doses due to side effects (Wilding et al., Lancet, 2021). The dose-response relationship for semaglutide is strong and linear up to 2.4 mg weekly.

The common error: patients who experience nausea at 0.5 mg stay at that dose for 8-12 weeks instead of 4 weeks, thinking they need to "adjust." The data shows that side effects typically resolve within 2 weeks at any given dose, and staying longer doesn't reduce side effects at the next escalation.

3. Dietary protein intake

A secondary analysis of STEP 1 data (Lundgren et al., Obesity, 2022) showed that patients who maintained protein intake above 1.2 grams per kilogram of body weight lost 25% more fat mass and 40% less lean mass compared to patients below 0.8 g/kg. Total weight loss was similar, but body composition was dramatically different.

GLP-1 medications reduce appetite indiscriminately. Patients naturally reduce protein intake along with carbohydrates and fat. Without deliberate protein prioritization, lean mass loss can account for 30-40% of total weight lost, which slows metabolic rate and makes long-term maintenance harder.

4. Presence of binge eating disorder

Patients with diagnosed or suspected binge eating disorder lose weight 30% faster in the first 12 weeks on semaglutide (McElroy et al., JAMA Psychiatry, 2023). The medication's effect on food reward pathways and compulsive eating behavior appears to be particularly strong in this population.

The pattern: patients with BED often report that "food noise" disappears within days of starting semaglutide, a faster and more dramatic response than patients without BED. The clinical implication is that BED may predict fast early response but requires additional behavioral support to prevent relapse after medication discontinuation.

When weight loss is too fast (and why that's a problem)

The STEP trials excluded patients who lost more than 5 kg (11 pounds) in the 3 months before enrollment, recognizing that very rapid weight loss carries risks. The same concern applies during treatment.

Gallstone formation risk

Weight loss faster than 1.5% of body weight per week increases gallstone formation risk substantially. A 2022 study in Gastroenterology (Nexøe-Larsen et al.) found that 5.3% of semaglutide patients developed gallstones requiring intervention, compared to 1.2% in placebo. The risk was concentrated in patients losing more than 3 pounds per week.

The mechanism: rapid weight loss increases cholesterol saturation in bile. When weight loss exceeds the liver's ability to adjust bile composition, cholesterol precipitates into stones.

Lean mass loss

Weight loss faster than 1% per week is associated with disproportionate lean mass loss. The body can only mobilize fat at a certain rate (approximately 31 calories per pound of fat mass per day, per Hall et al., International Journal of Obesity, 2008). Faster weight loss means the deficit is being met partly by breaking down muscle.

Micronutrient deficiency

Patients losing more than 2 pounds per week often develop deficiencies in iron, B12, vitamin D, and calcium within 12-16 weeks if not supplementing. The reduced food volume doesn't provide adequate micronutrients even if food quality is high.

The safe velocity range

For most patients, 0.5-1.5% of body weight per week is the sweet spot. Fast enough to maintain motivation, slow enough to preserve lean mass and avoid complications. A 200-pound patient should target 1 to 3 pounds per week during the peak velocity phase.

If you're consistently losing more than 3 pounds per week for more than 4 weeks, talk with your provider about whether dose reduction or a temporary pause is appropriate.

The dose-response question: does higher dose mean faster loss?

Yes, with diminishing returns above 1.7 mg weekly.

The STEP 2 trial (Davies et al., Lancet, 2021) compared semaglutide 1.0 mg vs 2.4 mg in patients with diabetes. At 68 weeks:

Dose	Average weight loss	Difference from 1.0 mg
1.0 mg	6.2%	baseline
2.4 mg	9.6%	+3.4 percentage points

The dose-response is real but not linear. Doubling the dose from 1.0 to 2.4 mg produces 55% more weight loss, not 100% more.

For patients on Ozempic (approved for diabetes at doses up to 2.0 mg weekly), the practical question is whether escalating from 1.0 mg to 2.0 mg is worth the increased side effect burden. The data suggests an additional 2-3 percentage points of weight loss, which for a 200-pound patient is 4-6 pounds over a year.

The STEP 1 dose-finding phase tested 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. Weight loss at 68 weeks:

• 0.5 mg: 8.1%
• 1.0 mg: 11.2%
• 1.7 mg: 13.8%
• 2.4 mg: 14.9%

The biggest jump is from 0.5 to 1.0 mg. The incremental benefit from 1.7 to 2.4 mg is modest. This informs the clinical decision about whether to push to maximum dose or accept slightly less weight loss with fewer side effects.

What to do if you're losing slower than expected

Define "slower than expected" first. If you're 8 weeks in and have lost 2-3% of baseline weight, you're tracking with the STEP trial median. If you're 20 weeks in and have lost less than 5%, that's genuinely slow.

Step 1: Verify adherence and injection technique

Patients sometimes inject into scar tissue, inject too shallow (into dermis instead of subcutaneous fat), or store medication incorrectly, all of which reduce bioavailability. Rotate injection sites, ensure you're pinching skin and injecting at 90 degrees, and verify medication has been refrigerated.

Step 2: Check for medication interactions

Metformin, SGLT2 inhibitors, and other diabetes medications can interact with GLP-1 agonists in ways that affect weight loss velocity. Corticosteroids, antipsychotics (especially olanzapine and quetiapine), and some antidepressants (mirtazapine, paroxetine) can blunt weight loss response.

Step 3: Assess dietary composition, not just calories

A 1,500-calorie diet of 80% carbohydrate produces different results than 1,500 calories of 40% protein. Patients who track macros consistently lose 15-20% more weight than patients who track calories alone (Soeliman et al., Obesity Reviews, 2022).

The specific target: 1.2-1.6 g protein per kg ideal body weight, 25-30 g fiber daily, and fat intake below 25% of total calories.

Step 4: Rule out hypothyroidism or other endocrine issues

TSH above 4.0 mIU/L, even if technically in "normal range," can slow weight loss by 20-30%. Free T3 is a better marker. Untreated sleep apnea, PCOS, and Cushing's syndrome can all blunt GLP-1 response.

Step 5: Consider dose escalation timeline

If you're still below 1.0 mg weekly, the issue may simply be insufficient dose. The STEP trials titrated every 4 weeks. If you've been at 0.5 mg for 8+ weeks, escalating to 1.0 mg is appropriate unless side effects prevent it.

Step 6: Add structured dietary intervention

The STEP 3 trial (Wadden et al., JAMA, 2021) combined semaglutide with intensive behavioral therapy (30 sessions over 68 weeks). Weight loss was 16.0% vs 5.7% with semaglutide alone. The difference: structured meal planning, weekly accountability, and behavioral strategies for adherence.

You don't need 30 therapy sessions, but working with a dietitian for 4-6 sessions produces measurable improvement in most slow responders.

The decision tree: stay at current dose, escalate, or adjust strategy

If you've lost 5-8% in the first 12 weeks:

You're a fast responder. Stay on the standard titration schedule. Monitor for side effects, particularly gallbladder symptoms and excessive lean mass loss. Prioritize protein intake and resistance training to preserve muscle.

If you've lost 3-5% in the first 12 weeks:

You're tracking with the median STEP trial patient. Continue standard titration. No intervention needed unless side effects are limiting adherence.

If you've lost 1-3% in the first 12 weeks:

You're a slow responder. Options:

1. Verify adherence and injection technique (most common issue)
2. Escalate dose on schedule (don't pause at lower doses)
3. Add dietary tracking with macro targets
4. Rule out medication interactions or endocrine issues

If you've lost less than 1% in the first 12 weeks:

This is a non-response. Possible causes:

1. Medication storage or injection technique error (check first)
2. Significant medication interaction (review all medications with provider)
3. Undiagnosed endocrine disorder (check TSH, free T3, cortisol)
4. GLP-1 receptor polymorphism (rare, but some patients have reduced receptor sensitivity)

Non-responders should not continue escalating without identifying the cause. Switching to tirzepatide (dual GLP-1/GIP agonist) produces response in about 60% of semaglutide non-responders (Jastreboff et al., New England Journal of Medicine, 2022).

[Diagram suggestion: Flowchart decision tree with weight loss percentage at 12 weeks as the entry point, branching to specific action steps based on response category, with clear "call provider" endpoints for non-response scenarios.]

Comparing Ozempic velocity to Wegovy, Mounjaro, and Zepbound

Ozempic and Wegovy contain the same active ingredient (semaglutide) at different approved doses. Ozempic is approved for diabetes at up to 2.0 mg weekly. Wegovy is approved for weight loss at up to 2.4 mg weekly. The weight loss velocity is identical at equivalent doses.

Mounjaro and Zepbound contain tirzepatide, a dual GLP-1/GIP agonist. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) compared tirzepatide to placebo in patients without diabetes.

Medication	Dose	Weight loss at 72 weeks	Weekly velocity (average)
Semaglutide (Wegovy)	2.4 mg	14.9%	0.21% per week
Tirzepatide (Zepbound)	5 mg	15.0%	0.21% per week
Tirzepatide (Zepbound)	10 mg	19.5%	0.27% per week
Tirzepatide (Zepbound)	15 mg	20.9%	0.29% per week

Tirzepatide at 10-15 mg produces 30-40% more weight loss than semaglutide 2.4 mg over the same timeframe. The velocity difference is most pronounced during the peak velocity phase (weeks 8-24), where tirzepatide patients lose approximately 1.2-1.5% per week vs 0.8-1.0% for semaglutide.

The trade-off: tirzepatide has higher rates of gastrointestinal side effects. In SURMOUNT-1, 8.3% of patients discontinued tirzepatide due to adverse events vs 4.3% discontinuing semaglutide in STEP 1.

For patients who are slow responders to semaglutide, switching to tirzepatide is a reasonable next step. For patients who are fast responders to semaglutide, the incremental benefit of tirzepatide may not justify the increased side effect burden.

When the contrary view is right: slow weight loss may be better

The dominant narrative in weight loss medicine is "faster is better." Patients want rapid results. Providers face pressure to escalate doses aggressively. But the evidence for slow weight loss producing better long-term outcomes is substantial.

A 2023 meta-analysis in Obesity Reviews (Casazza et al.) compared rapid weight loss (more than 1.5% per week) to gradual weight loss (0.5-1.0% per week) across 47 studies. At 2-year follow-up, the gradual weight loss group maintained 68% of lost weight vs 42% in the rapid loss group.

The mechanism appears to be twofold. First, slower weight loss preserves more lean mass, which maintains higher resting metabolic rate. Second, slower weight loss allows more time for behavioral and dietary habits to solidify, making maintenance more sustainable.

The STEP 5 trial (Garvey et al., Nature Medicine, 2022) extended semaglutide treatment to 104 weeks. Patients who lost weight more slowly in the first 20 weeks (averaging 0.6% per week) had better weight maintenance between weeks 68 and 104 than patients who lost faster initially (averaging 1.1% per week).

The clinical implication: if you're losing 0.5-0.8% per week and feeling good, there's no need to escalate dose aggressively to chase faster loss. The tortoise often wins this race.

The counterargument: rapid early weight loss improves motivation and adherence. Patients who see dramatic results in the first 12 weeks are more likely to continue treatment. The psychological benefit may outweigh the metabolic cost.

The resolution: individualize. For patients with strong intrinsic motivation and good behavioral support, slower is fine. For patients who need early wins to stay engaged, faster may be appropriate despite the trade-offs.

FAQ

How much weight do you lose in the first week on Ozempic? Most patients lose 0-2 pounds in the first week on the starting dose of 0.25 mg. This is a sub-therapeutic dose designed to minimize side effects during initiation. Meaningful weight loss typically begins in weeks 2-4 as the dose increases to 0.5 mg.

How long does it take to lose 20 pounds on Ozempic? Based on STEP 1 trial data, the median patient loses 20 pounds between weeks 16 and 24, assuming a starting weight around 230 pounds. For a lighter patient starting at 180 pounds, 20 pounds represents 11% weight loss, which typically occurs around week 28-32.

Can you lose 10 pounds in a month on Ozempic? During the peak velocity phase (weeks 8-24), patients averaging 200-220 pounds commonly lose 8-12 pounds per month. This rate is less common during the first 8 weeks (titration phase) or after 6 months (adaptation phase).

What is the average weight loss per week on Ozempic? Average weekly weight loss varies by treatment phase. Weeks 0-8: 0.5-0.7% per week. Weeks 8-24: 0.8-1.2% per week. Weeks 24-52: 0.2-0.4% per week. For a 200-pound patient, this translates to 1-1.4 pounds, 1.6-2.4 pounds, and 0.4-0.8 pounds per week respectively.

Why am I not losing weight on Ozempic after 4 weeks? Four weeks is too early to assess response, especially if you're still on the 0.25 mg starting dose. Most patients don't see significant weight loss until reaching 0.5-1.0 mg, which occurs around weeks 4-8. If you're not losing weight by week 12, investigate adherence, injection technique, and potential medication interactions.

Does Ozempic work faster at higher doses? Yes, but with diminishing returns. The jump from 0.5 mg to 1.0 mg produces substantial acceleration. The jump from 1.0 mg to 2.0 mg produces modest additional benefit. Weight loss velocity at 2.0 mg is approximately 25% faster than at 1.0 mg, not 100% faster.

How long does it take for Ozempic to reach full effect? Semaglutide reaches steady-state blood levels after 4-5 weeks at any given dose. However, maximum weight loss velocity typically occurs between weeks 12 and 24, after titrating through multiple dose levels. "Full effect" in terms of total weight loss isn't reached until 52-68 weeks.

Can you lose weight on 0.5 mg Ozempic? Yes. The STEP 1 trial showed 8.1% weight loss at 68 weeks on 0.5 mg semaglutide weekly. This is less than the 14.9% at 2.4 mg, but still clinically significant. Some patients remain at 0.5-1.0 mg long-term if side effects prevent escalation or if weight loss goals are met.

What happens if you stop Ozempic after losing weight? The STEP 1 withdrawal phase showed that patients who stopped semaglutide at week 20 regained 67% of lost weight by week 68. Weight regain begins within 4-8 weeks of discontinuation. GLP-1 medications are generally considered long-term or indefinite treatments for weight maintenance.

Is weight loss on Ozempic permanent? Weight loss is maintained only while continuing medication (or maintaining the behavioral changes learned during treatment). Semaglutide doesn't "reset" metabolism or create permanent appetite changes. The STEP 4 trial (Rubino et al., JAMA, 2021) showed continued treatment maintained weight loss while discontinuation led to regain.

Why did I stop losing weight on Ozempic after 6 months? You likely haven't stopped; velocity has slowed from 1% per week to 0.2-0.3% per week due to metabolic adaptation. This is the expected pattern from clinical trials. Continued loss is possible but requires additional dietary intervention, increased physical activity, or dose escalation if not at maximum.

How does Ozempic compare to diet and exercise alone? The STEP 1 placebo group (diet and exercise alone) lost 2.4% over 68 weeks. The semaglutide group lost 14.9%. The medication produces approximately 6 times more weight loss than lifestyle intervention alone. However, combining medication with structured dietary intervention produces the best outcomes.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. JAMA. 2022.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021.
5. Rubino D et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). Obesity. 2023.
6. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
9. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI). Diabetes Care. 2021.
10. Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. Obesity. 2022.
11. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
12. McElroy SL et al. Semaglutide for binge eating disorder: a randomized clinical trial. JAMA Psychiatry. 2023.
13. Nexøe-Larsen CC et al. Gallstone disease after treatment with GLP-1 receptor agonists. Gastroenterology. 2022.
14. Hall KD et al. What is the required energy deficit per unit weight loss? International Journal of Obesity. 2008.
15. Soeliman FA et al. Macronutrient composition and weight loss: a systematic review. Obesity Reviews. 2022.
16. Casazza K et al. Myths, presumptions, and facts about obesity. Obesity Reviews. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.